UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 179

Sortiert nach

Improved survival for extremity soft tissue sarcoma treated in high‐volume facilities

Journal of surgical oncology, 2018-06, Vol.117 (7), p.1479-1486

2018

Volltextzugriff (PDF)

Epigenetic silencing of the human NOS2 gene: rethinking the role of nitric oxide in human macrophage inflammatory responses

The Journal of immunology (1950), 2014-03, Vol.192 (5), p.2326-2338

2014

Volltextzugriff (PDF)

Results of an International Randomized Phase III Trial of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus Versus Placebo to Control Metastatic Sarcomas in Patients After Benefit From Prior Chemotherapy

Journal of clinical oncology, 2013-07, Vol.31 (19), p.2485-2492

2013

Volltextzugriff (PDF)

Quantitative computed tomography determined regional lung mechanics in normal nonsmokers, normal smokers and metastatic sarcoma subjects

PloS one, 2017-07, Vol.12 (7), p.e0179812-e0179812

2017

Volltextzugriff (PDF)

Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial

Journal for immunotherapy of cancer, 2023-05, Vol.11 (5), p.e006270

2023

Volltextzugriff (PDF)

Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy

BMC cancer, 2018-02, Vol.18 (1), p.225-225, Article 225

2018

Volltextzugriff (PDF)

Efficacy of nelfinavir as monotherapy in refractory adenoid cystic carcinoma: Results of a phase II clinical trial

Head & neck, 2015-05, Vol.37 (5), p.722-726

2015

Volltextzugriff (PDF)

Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma

Journal of clinical oncology, 2018-06, Vol.36 (17), p.1658-1667

2018

Volltextzugriff (PDF)

Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials

The lancet oncology, 2018-03, Vol.19 (3), p.416-426

2018

Volltextzugriff (PDF)

Melanoma Brain Metastases in the Era of Targeted Therapy and Checkpoint Inhibitor Therapy

Cancers, 2021-03, Vol.13 (7), p.1489

2021

Volltextzugriff (PDF)

Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma

Journal of clinical oncology, 2016-08, Vol.34 (22), p.2619-2626

2016

Volltextzugriff (PDF)

Surgical management for giant bladder leiomyosarcoma

Urology case reports, 2022-05, Vol.42, p.101995, Article 101995

2022

Volltextzugriff (PDF)

Neoadjuvant Radiotherapy-Related Wound Morbidity in Soft Tissue Sarcoma: Perspectives for Radioprotective Agents

Cancers, 2020-08, Vol.12 (8), p.2258

2020

Volltextzugriff (PDF)

The Impact of TSC-1 and -2 Mutations on Response to Therapy in Malignant PEComa: A Multicenter Retrospective Analysis

Genes, 2022-10, Vol.13 (11), p.1932

2022

Volltextzugriff (PDF)

Presumed Melanoma of Unknown Primary Origin Metastatic to the Choroid Mimics Primary Uveal Melanoma

Case reports in ophthalmology, 2021-12, Vol.12 (3), p.987-993

2021

Volltextzugriff (PDF)

Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma

Cancer discovery, 2021-12, Vol.11 (12), p.2998-3007

2021

Volltextzugriff (PDF)

Sorafenib for Advanced and Refractory Desmoid Tumors

The New England journal of medicine, 2018-12, Vol.379 (25), p.2417-2428

2018

Volltextzugriff (PDF)

The Midwest Sarcoma Trials Partnership: Bridging Academic and Community Networks in a Collaborative Approach to Sarcoma

Journal of clinical medicine, 2023-03, Vol.12 (7), p.2561

2023

Volltextzugriff (PDF)

Correction to: Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy

BMC cancer, 2018-04, Vol.18 (1), p.413-413, Article 413

2018

Volltextzugriff (PDF)

Turning ‘Cold’ tumors ‘Hot’: immunotherapies in sarcoma

Annals of translational medicine, 2021-06, Vol.9 (12), p.1039-1039

2021

Volltextzugriff (PDF)

A phase II clinical study of 13‐deoxy, 5‐iminodoxorubicin (GPX‐150) with metastatic and unresectable soft tissue sarcoma

Cancer medicine (Malden, MA), 2019-06, Vol.8 (6), p.2994-3003

2019

Volltextzugriff (PDF)

Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma

British journal of cancer, 2019-08, Vol.121 (5), p.417-420

2019

Volltextzugriff (PDF)

Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial

JAMA : the journal of the American Medical Association, 2014-06, Vol.311 (23), p.2397

2014

Volltextzugriff (PDF)

1 – 25 von 179

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(165)
Mit Volltextzugriff
(172)

Publikationsform

Sprache

Englisch
(178)
Japanisch
(16)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Improved survival for extremity soft tissue sarcoma treated in high‐volume facilities

Epigenetic silencing of the human NOS2 gene: rethinking the role of nitric oxide in human macrophage inflammatory responses

Results of an International Randomized Phase III Trial of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus Versus Placebo to Control Metastatic Sarcomas in Patients After Benefit From Prior Chemotherapy

Quantitative computed tomography determined regional lung mechanics in normal nonsmokers, normal smokers and metastatic sarcoma subjects

Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial

Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy

Efficacy of nelfinavir as monotherapy in refractory adenoid cystic carcinoma: Results of a phase II clinical trial

Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma

Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials

Melanoma Brain Metastases in the Era of Targeted Therapy and Checkpoint Inhibitor Therapy

SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors

Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma

Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016)

Surgical management for giant bladder leiomyosarcoma

Neoadjuvant Radiotherapy-Related Wound Morbidity in Soft Tissue Sarcoma: Perspectives for Radioprotective Agents

The Impact of TSC-1 and -2 Mutations on Response to Therapy in Malignant PEComa: A Multicenter Retrospective Analysis

Presumed Melanoma of Unknown Primary Origin Metastatic to the Choroid Mimics Primary Uveal Melanoma

Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma

Sorafenib for Advanced and Refractory Desmoid Tumors

The Midwest Sarcoma Trials Partnership: Bridging Academic and Community Networks in a Collaborative Approach to Sarcoma

Correction to: Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy

Turning ‘Cold’ tumors ‘Hot’: immunotherapies in sarcoma

A phase II clinical study of 13‐deoxy, 5‐iminodoxorubicin (GPX‐150) with metastatic and unresectable soft tissue sarcoma

Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma

Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial

Suchergebnisse filtern